Animal-based radiation absorbed dose evaluation of holmium-۱۶۶ labeled hydroxyapatite particulates in liver malignancies

Objective(s): Liver malignancies are among the most prevalent causes of cancer-related deaths worldwide. Intra-arterial administration of particulates labeled with beta-emitting radionuclides is one of the non-surgical promising modalities for the treatment of liver cancer.Methods: In this work, the radiation absorbed dose of ۱۶۶Ho-hydroxyapatite (۱۶۶Ho-HA) radiopharmaceutical was estimated for adult men based on biodistribution data in normal Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology were applied.Results: The results show that more than ۸۴% of the absorbed dose is localized in liver tissue (۷.۳۵ mGy MBq-۱). Also, radiation absorbed doses of ۱۶۶Ho-HA for red bone marrow, osteogenic cells, and spleen tissues were estimated to be about ۰.۱۸, ۰.۳۸, and ۰.۲۴ mGy MBq-۱, respectively. The maximum administrated activity was obtained at ۸۷.۵ MBq kg-۱ of body weight with an effective dose of ۰.۳۹ mSv MBq-۱. The maximum tolerable dose (MTD) for liver tissue was ۶.۱۳ GBq (۱۶۵.۵۶ mCi).Conclusion: This study indicated that ۱۶۶Ho-HA can provide an impressive dose for liver cancer malignancies with an insignificant dose to healthy tissues.

کلیدواژه ها:

۱۶۶Ho-HA ، Liver cancer therapy ، Absorbed Dose ، MIRD method ، Wistar rat